NCT00618618View on ClinicalTrials.gov

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Moderate or Severe Submental Fullness
Interventions
DRUG

Deoxycholic Acid Injection

Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

DRUG

Placebo

Trial Locations (7)

2000

Investigational Site, Sydney

3142

Investigational Site, Toorak

L2E 7H1

Investigational Site, Niagara Falls

L6J 7W5

Investigational Site, Oakville

M4V 1R1

Investigational Site, Toronto

M5S 3B4

Investigational Site, Toronto

M68HD

Investigational Site, Manchester

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY

NCT00618618 - Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | Biotech Hunter | Biotech Hunter